Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25656908 | 0.83 | TSHR (0.50) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL3122161 | 0.82 | ALDH1A1 (0.34) | ALDH1A1HSD17B10CA12CA1CA2 | |
| SCHEMBL26657547 | 0.82 | TSHR (0.46) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL2367874 | 0.82 | TSHR (0.48) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL7999276 | 0.80 | TSHR (0.47) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL27826070 | 0.80 | LMNA (0.36) | ALDH1A1 | |
| SCHEMBL2368148 | 0.78 | MEN1 (0.47) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL578659 | 0.78 | TSHR (0.52) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL31602059 | 0.78 | MEN1 (0.47) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL23250822 | 0.78 | MEN1 (0.58) | TSHRMAPK1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092724-A1 | NEW BIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMER | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2024-03-21 | — | — | US | disclosed |
| US-11919850-B2 | Bifunctional (meth)acrylate compound and polymer | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2024-03-05 | — | — | US | disclosed |
| EP-3763751-A1 | NEW BIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMER | Maruzen Petrochemical Co., Ltd. (JP) | 2021-01-13 | — | — | EP | disclosed |
| US-20200392066-A1 | NEW BIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMER | Maruzen Petrochrmical Co., Ltd. (JP) | 2020-12-17 | — | — | US | disclosed |
| WO-2019171958-A1 | NEW BIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMER | 丸善石油化学株式会社 | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392066-A1 | NEW BIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMER | RAD51, WDR1, TET1 | TSHR 4083/4885MAPK1 1634/4885ALDH1A1 960/4885 |
| US-20240092724-A1 | NEW BIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMER | RAD51, WDR1, TET1 | TSHR 4083/4885MAPK1 1634/4885ALDH1A1 960/4885 |
| US-11919850-B2 | Bifunctional (meth)acrylate compound and polymer | DNMT1, RAD51, ASH1L | TSHR 3623/4885MAPK1 1441/4885ALDH1A1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.